First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis

Current Oncology, Journal Year: 2025, Volume and Issue: 32(3), P. 148 - 148

Published: March 4, 2025

Background: HER2 mutations are rare driver events in advanced NSCLC, with limited relief from current targeted therapies. This study aimed to characterize the molecular features of HER2-mutant NSCLC and evaluate clinical efficacy pyrotinib-based combination therapy as a first-line treatment, providing evidence for optimizing treatment strategies. Methods: patients diagnosed at Jiangsu Province People’s Hospital 2016 2024 were enrolled. HER2-positive cases screened by IHC/FISH further profiled NGS. Treatment response was assessed RECIST 1.1, survival analysis performed using Kaplan–Meier log-rank tests. Results: Among 144 confirmed NGS, 10 insertion mutations, 26 missense 2 fusion identified. The most common mutation exon 20 p.A775_G776insYVMA (47.9%), TP53 frequent co-mutation (10.4%). In terms efficacy, demonstrated significant benefit, an ORR 33.3%, DCR 95.2%, median PFS (mPFS) 11.3 months (95% CI: 10.27–12.26), OS (mOS) 21.0 18.00–23.94). Subgroup revealed no impact subtype or status on but brain metastases had significantly worse prognosis than those without metastasis (mPFS: 5.1 vs. 12.9 months, p < 0.01; mOS: 9.3 26.5 0.01). All TRAEs grade 1–3 (any grade: 90.5%; 3: 14.3%), TRAE being diarrhea 85.7%; 9.5%). Conclusions: Pyrotinib-based is feasible demonstrating benefits manageable toxicity. However, require enhanced comprehensive management.

Language: Английский

The role of Wnt/β-catenin signaling in lung cancer progression and therapy: a comprehensive review

Medical Oncology, Journal Year: 2025, Volume and Issue: 42(6)

Published: April 27, 2025

Language: Английский